QUEBEC CITY, April 17, 2014 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)
(OTCQX: DGCRF) (the "Corporation") today announced that its
shareholders have approved all resolutions presented to them in the
Management Proxy Circular dated March 14, 2014 and put forth for vote
during the shareholders meeting held today in Montreal.
Shareholders re-elected Dr. Yves Fradet, Dr. Louise Proulx, Mr. Andrew
Sheldon, Dr. Jacques Simoneau, and Dr. Vincent R. Zurawski as directors
of the Corporation.
The election results for the Board of directors are as follows:
Andrew J. Sheldon
Vincent R. Zurawski
Shareholders also reappointed Ernst & Young as auditors of the
Corporation and reconfirmed DiagnoCure's Shareholders Rights Plan.
The presentation given by Dr. Yves Fradet after completion of the formal
business portion of the meeting today is available on DiagnoCure's
website at www.diagnocure.com through a link on the Investors page; Presentations.
"DiagnoCure's primary focus is to secure shareholder value by ensuring
the full commercial potential of PCA3". stated Dr. Yves Fradet.
Chairman of the Board and President and Chief Medical Officer of the
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008. the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license on the diagnostic applications of its
proprietary molecular biomarker PCA3 to Gen-Probe. now a wholly-owned
subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate
cancer test is commercialized in Europe under CE mark and is approved
for commercialization in Canada and the United States. For more
information. please visit www.diagnocure.com.
This release may contain forwardlooking statements that involve known
and unknown risks. uncertainties and assumptions that may cause actual
results to differ materially from those expected. Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates". "assumes".
"believes". "estimates". "expects". "intend". "may". "plans".
"projects". "should". "will". or the negative thereof or other
variations thereon. Forward-looking statements also include any other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the "safe-harbour"
provisions of applicable Canadian securities laws. By their very
nature. forwardlooking statements are based on expectations and
hypotheses and also involve risks and uncertainties. known and unknown.
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors and
others in understanding certain key elements of the Corporation's
current objectives. strategic priorities. expectations and plans. and
in obtaining a better understanding of the Corporation's business and
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes and that they
should not place undue reliance on these forwardlooking statements.
For instance. any forward-looking statements regarding the outcome of
research and development projects. clinical studies and future
revenues. including those related to PROGENSA® PCA3. are based on
management expectations and such outcome may vary materially depending
on global political and economic conditions. dependence on
collaboration partners. uncertainty of healthcare reimbursement. and
marketing and distribution challenges. In addition. the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly update
or revise any forwardlooking statements contained herein unless
required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.